secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2021-12-03T23:59:59+00:00
Accession:  0001564590-21-059298
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera appoints Neil Aubuchon as Chief Commercial Officer
------------------------------------------------------------

- Neil Aubuchon named CCO effective December 2, 2021; will lead commercial strategy and partnership evaluation.
- Aubuchon brings over 20 years experience from Amgen, Lilly, and Santen, including global marketing roles.
- CEO Carl Hansen cited Aubuchon's commercial experience as key to expanding AbCellera's deal structures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000156459021059298/0001564590-21-059298-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000156459021059298/abcl-8k_20211202.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-059298

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer